The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats

Kidney and Blood Pressure Research

Volumn 30, Issue 5, 2007, Pages 335-346

  Čertíková Chábová, Věra ^a   Kramer, Herbert J ^c   Vaněčková, Ivana ^a,b   Thumová, Monika ^a,b   Škaroupková, Petra ^a   Tesař, Vladimír ^a   Falck, John R ^d   Imig, John D ^e   Červenka, Luděk ^a,b,f  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Ctr for Exp Cardiovasc Research   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

20 Hydroxyeicosatetraenoic acid; Cytochrome P 450; Epoxyeicosatrienoic acid; Glomerular filtration rate; Hypertension; Renal plasma flow; Renin transgenic rats; Renin angiotensin system; Sodium excretion

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; CYTOCHROME P450 4A; EPOXYICOSATRIENOIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ELECTROLYTE EXCRETION; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CONCENTRATING CAPACITY; KIDNEY CORTEX; KIDNEY FUNCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL ARTERY; SODIUM EXCRETION; TRANSGENIC RAT; WESTERN BLOTTING;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARACHIDONIC ACIDS; BLOOD PRESSURE; HYDROXYEICOSATETRAENOIC ACIDS; HYPERTENSION; KIDNEY; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 34748856828     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107710     Document Type: Article

References (61)

1. Hall JE, Brands MW: The renin-angiotensin-aldosterone system: renal mechanisms and circulatory homeostasis; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. Philadelphia, Lippincott Williams & Wilkins, 2000, pp 1009-1046.
2. Navar LG: The intrarenal renin-angiotensin system in hypertension. Kidney Int 2004;65:1522-1532.
3. Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH: Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonamide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens 2001;19:983-992.
4. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 2002;82:131-185.
5. Dos Santos EA, Dahly-Vernon AJ, Hoagland KM, Roman RJ: Inhibition of the formation of EETs and 20-HETE with 1-aminobenzotriazole attenuates pressure natriuresis. Am J Physiol 2004;287:R58-R68.
6. Imig JD: Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol 2005;289:F496-F503.
7. Sarkis A, Lopez B, Roman RJ: Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens 2004;13:205-214.
8. Zhao X, Imig JD: Kidney CYP450 enzymes: biological actions beyond drug metabolism. Curr Drug Metab 2003;4:73-84.
9. Carroll MA, Kemp R, Cheng MK, McGiff JC: Regulation of preglomerular microvascular 20-hydroxyeicosatetraenoic acid levels by salt depletion. Med Sci Monit 2001;7:567-572.
10. Croft KD, McGiff JC, Sanchez-Mendoza A, Carroll MA: Angiotensin II releases 20-HETE from rat renal microvessels. Am J Physiol 2000;279:F544-F551.
11. Alonso-Galicia M, Maier KG, Greene AS, Cowley AW, Roman RJ: Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol 2002;283:R60-R68.
12. Joly E, Seqqat R, Flamion B, Caron N, Michal A, Imig JD, Kramp R: Increased renal vascular reactivity to ANG II after unilateral nephrectomy in the rat involves 20-HETE. Am J Physiol 2006;291:R977-R986.
13. Muthalif MM, Karzoun NA, Gaber L, Khandekar Z, Benter IF, Saeed AF, Parmentier JH, Estes A, Malik KU: Angiotensin II-induced hypertension: contribution of Ras GTPase/mitogen-activated protein kinase and cytochrome P-450 metabolites. Hypertension 2000;36:604-609.
14. Zou AP, Imig JD, Ortiz de Montellano PR, Sui Z, Falck JR, Roman RJ: Effect of P-450 ω-hydrolase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 1994;266:F934-F941.
15. Mullins JJ, Peters J, Ganten D: Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature 1990;344:541-544.
16. Kopkan L, Kramer HJ, Huskova Z, Vaňourková Z, Škaroupková P, Thumová M, C7caron;ervenka L: The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens 2005;23:1531-1539.
17. Jacinto SM, Mullins JJ, Mitchell KD: Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol 1999;276:F315-F322.
18. Mitchell KD, Mullins JJ: ANG II dependence of tubuloglomerular feedback responsiveness in hypertensive ren-2 transgenic rats. Am J Physiol 1995;268:F821-F828.
19. 1 receptor blockade in hypertensive Ren-2 transgenic rats. J Hypertens 2004;22:819-825.
20. Husková Z, Kramer HJ, Vaňourková Z, ?ervenka L: Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens 2006;24:517-527.
21. Husková Z, Kramer HJ, Thumová M, Vaňurková Z, Bürgelová M, Teplan V, Malý J, Červenka L: Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 2006;29:74-83.
22. Hartner A, Porst M, Klanke B, Cordasic N, Veelken R, Hilgers KF: Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats. Nephrol Dial Transplant 2006;21:1778-1785.
23. Imig JD: Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am J Hypertens 2000;13:810-818.
24. Kroetz DL, Xu F: Regulation and inhibition of arachidonic acid ω-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 2005;45:413-438.
25. Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML: Cytochrome P-450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther 1998;284:966-973.
26. Maier KG, Henderson L, Narayanan J, Alonso-Galicia M, Falck JR, Roman RJ: Fluorescent HPLC assay for 20-HETE and other P-450 metabolites of arachidonic acid. Am J Physiol 2000;279:R579-R589.
27. 1 receptor blockade in nonclipped kidneys of Goldblatt hypertensive rats. Hypertension 1999;33:102-107.
28. Kobori H, Nishiyama A, Abe Y, Navar LG: Urinary angiotensinogen as an indicator of intrarenal status in hypertension. Hypertension 2003;41:42-49.
29. + channel in renal arterioles. Am J Physiol 1996;270:R228-R237.
30. Randriamboavonjy V, Kiss L, Falck JR, Busse R, Fleming I: The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation. Cardiovasc Res 2005;65:487-494.
31. 2+ current. J Physiol 1998;507:771-781.
32. Randriamboavonjy V, Busse R, Fleming I: 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase. Hypertension 2003;41:801-806.
33. Kaide J, Wang MH, Wang JS, Zhang F, Gopal VR, Falck JR, Nasjletti A, Laniado-Schwartzman M: Transfection of CYP4A1 cDNA increases vascular reactivity in renal interlobar arteries. Am J Physiol 2003;284:F51-F56.
34. Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW: Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension 2000;35:307-312.
35. Oyekan AO, McGiff JC: Cytochrome P-450-derived eicosanoids participate in the renal functional effects of ET-1 in the anesthetized rat. Am J Physiol 1998;274:R52-R61.
36. Imig JD, Zou AP, Ortiz de Montellano PR, Sui Z, Roman RJ: Cytochrome P-450 inhibitors alter afferent arteriolar responses to elevations in pressure. Am J Physiol 1996;266:H1879-H1885.
37. Imig JD, Falck JR, Inscho EW: Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. Br J Pharmacol 1999;127:1399-1405.
38. Quigley R, Baum M, Reddy KM, Griener JC, Falck JR: Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol 2000;278:F949-F953.
39. Escalante B, Erlij D, Falck JR, McGiff JC: Cytochrome P-450 arachidonate metabolites affect ion fluxes in rabbit medullary thick ascending limb. Am J Physiol 1994;266:C1775-C1782.
40. +-ATPase activity in the thick ascending loop of Henle. Am J Physiol 2007;292:R2400-R2405.
41. Ma YH, Schwartzman ML, Roman RJ: Altered renal P-450 metabolism of arachidonic acid in Dahl salt-sensitive rats. Am J Physiol 1994;267:R579-R589.
42. Hoagland KM, Flasch AK, Roman RJ: Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension 2003;42:669-673.
43. Granger JP: Pressure natriuresis. Role of renal interstitial hydrostatic pressure. Hypertension 1992;19:I9-I17.
44. Roman RJ, Cowley AW Jr, Garcia-Estan J, Lombard JH: Pressure-diuresis in volume-expanded rats. Cortical and medullary hemodynamics. Hypertension 1998;12:168-176.
45. Wiliams JM, Sarkis A, Lopez B, Ryan RP, Flasch AK, Roman RJ: Elevations in renal interstitial hydrostatic pressure and 20-hydroxyeicosatetraenoic acid contribute to pressure natriuresis. Hypertension 2007;49:687-694.
46. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR: Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 1996;7:2364-2370.
47. + channel activity. Am J Physiol 1996;270:F822-F832.
48. + channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ Res 1997;80:877-884.
49. + channels in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. Eur J Pharmacol 1993;230:215-221.
50. Imig JD, Falck JR, Wei S, Capdevila JH: Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilatation in response to bradykinin. J Vasc Res 2001;38:247-255.
51. Wang D, Borrego-Conde LJ, Falck JR, Sharma KK, Wilcox CS, Umans JG: Contribution of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. Kidney Int 2003;63:2187-2193.
52. Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-423.
53. 2 and modulation by lipoxygenase and P-450 pathways: Am J Physiol 1997;273:F274-F282.
54. Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG: An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest 1991;88:456-461.
55. Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD: 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol 1995;268:F931-F939.
56. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, Kim IH, Watanabe T, Hammock BD: An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 2005;46:975-981.
57. Kaergel E, Muller DN, Honeck H, Theuer J, Shagdarsuren E, Mullally A, Luft FC, Schunck WH: P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 2002;40:273-279.
58. Messer-Letienne I, Bernard N, Roman RJ, Sassard J, Benzoni D: Cytochrome P-450 arachidonate metabolite inhibition improves renal function in Lyon hypertensive rats. Am J Hypertens 1999;12:398-404.
59. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD: Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol 2004;15:1244-1253.
60. Zhao X, Pollock DM, Inscho EW, Zelding DC, Imig JD: Decreased renal CYP2C enzymes and impaired vasodilation are associated with salt-sensitive hypertension. Hypertension 2003;41:709-714.
61. Imig JD: Cardiovascular therapeutic aspects of soluble epoxide hydrolase inhibitors. Cardiovasc Drug Rev 2006;24:169-188.